Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

@inproceedings{Patel2013EmergingMT,
  title={Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer},
  author={Jesal C. Patel and Benjamin L. Maughan and Archana M. Agarwal and Julia A. Batten and Tian yi Zhang and Neeraj Agarwal},
  booktitle={Prostate cancer},
  year={2013}
}
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the last decade, it has been recognized that despite the failure of ADT, most prostate cancers maintain some dependence on androgen and/or androgen receptor (AR) signaling for proliferation. Furthermore… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Similar Papers

Loading similar papers…